These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 29224639)

  • 1. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
    Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.
    Azizi M; Schmieder RE; Mahfoud F; Weber MA; Daemen J; Davies J; Basile J; Kirtane AJ; Wang Y; Lobo MD; Saxena M; Feyz L; Rader F; Lurz P; Sayer J; Sapoval M; Levy T; Sanghvi K; Abraham J; Sharp ASP; Fisher NDL; Bloch MJ; Reeve-Stoffer H; Coleman L; Mullin C; Mauri L;
    Lancet; 2018 Jun; 391(10137):2335-2345. PubMed ID: 29803590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
    Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
    Azizi M; Sanghvi K; Saxena M; Gosse P; Reilly JP; Levy T; Rump LC; Persu A; Basile J; Bloch MJ; Daemen J; Lobo MD; Mahfoud F; Schmieder RE; Sharp ASP; Weber MA; Sapoval M; Fong P; Pathak A; Lantelme P; Hsi D; Bangalore S; Witkowski A; Weil J; Kably B; Barman NC; Reeve-Stoffer H; Coleman L; McClure CK; Kirtane AJ;
    Lancet; 2021 Jun; 397(10293):2476-2486. PubMed ID: 34010611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.
    Azizi M; Sharp ASP; Fisher NDL; Weber MA; Lobo MD; Daemen J; Lurz P; Mahfoud F; Schmieder RE; Basile J; Bloch MJ; Saxena M; Wang Y; Sanghvi K; Jenkins JS; Devireddy C; Rader F; Gosse P; Claude L; Augustin DA; McClure CK; Kirtane AJ;
    Circulation; 2024 Mar; 149(10):747-759. PubMed ID: 37883784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
    Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials.
    Kirtane AJ; Sharp ASP; Mahfoud F; Fisher NDL; Schmieder RE; Daemen J; Lobo MD; Lurz P; Basile J; Bloch MJ; Weber MA; Saxena M; Wang Y; Sanghvi K; Jenkins JS; Devireddy C; Rader F; Gosse P; Sapoval M; Barman NC; Claude L; Augustin D; Thackeray L; Mullin CM; Azizi M;
    JAMA Cardiol; 2023 May; 8(5):464-473. PubMed ID: 36853627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.
    Desch S; Okon T; Heinemann D; Kulle K; Röhnert K; Sonnabend M; Petzold M; Müller U; Schuler G; Eitel I; Thiele H; Lurz P
    Hypertension; 2015 Jun; 65(6):1202-8. PubMed ID: 25824248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.
    Voora R; Hinderliter AL
    Curr Hypertens Rep; 2018 Sep; 20(11):92. PubMed ID: 30194545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
    Weber MA; Mahfoud F; Schmieder RE; Kandzari DE; Tsioufis KP; Townsend RR; Kario K; Böhm M; Sharp ASP; Davies JE; Osborn JW; Fink GD; Euler DE; Cohen DL; Schlaich MP; Esler MD
    JACC Cardiovasc Interv; 2019 Jun; 12(12):1095-1105. PubMed ID: 31221299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.
    Azizi M; Saxena M; Wang Y; Jenkins JS; Devireddy C; Rader F; Fisher NDL; Schmieder RE; Mahfoud F; Lindsey J; Sanghvi K; Todoran TM; Pacella J; Flack J; Daemen J; Sharp ASP; Lurz P; Bloch MJ; Weber MA; Lobo MD; Basile J; Claude L; Reeve-Stoffer H; McClure CK; Kirtane AJ;
    JAMA; 2023 Feb; 329(8):651-661. PubMed ID: 36853250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial.
    Kandzari DE; Bhatt DL; Sobotka PA; O'Neill WW; Esler M; Flack JM; Katzen BT; Leon MB; Massaro JM; Negoita M; Oparil S; Rocha-Singh K; Straley C; Townsend RR; Bakris G
    Clin Cardiol; 2012 Sep; 35(9):528-35. PubMed ID: 22573363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications.
    Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M
    Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal Denervation in the Management of Resistant Hypertension: A Comprehensive Review of Literature.
    Salehin S; Karnkowska B; Hamza I; Malik H; Syeda D; Hasan SM; Rangasetty U; Gilani S; Jneid H; Raja M
    Curr Probl Cardiol; 2024 Feb; 49(2):102137. PubMed ID: 37863457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design.
    Böhm M; Townsend RR; Kario K; Kandzari D; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Hickey GL; Fahy M; DeBruin V; Brar S; Pocock S
    Clin Res Cardiol; 2020 Mar; 109(3):289-302. PubMed ID: 32034481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN).
    Fengler K; Rommel KP; Blazek S; Besler C; Hartung P; von Roeder M; Petzold M; Winkler S; Höllriegel R; Desch S; Thiele H; Lurz P
    Circulation; 2019 Jan; 139(5):590-600. PubMed ID: 30586691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.